Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on August 21, 2017. The filing addresses corporate governance changes and regulatory updates regarding a securities offering.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a potential capital raise: the company has a sales agreement to offer and sell up to $10,000,000 of common stock under a Controlled Equity Offering SM with Cantor Fitzgerald & Co.
Material Changes
- Executive Departure: Clayton D. Edwards resigned as Chief Operations Officer effective immediately on August 21, 2017. The company stated the resignation was not due to any disagreement with the Company or its operations.
- Securities Offering Update: The company received a legal opinion in connection with its Form S-3 Registration Statement (No. 333-218308) and a related prospectus supplement dated August 25, 2017, covering the aforementioned $10 million equity offering.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of specific risks beyond the standard disclosure of the executive departure. The primary focus is the administrative completion of the legal opinion required for the ongoing equity offering.
Investor Verification Checklist
- Verify the replacement for the Chief Operations Officer position.
- Confirm the status and execution of the $10 million Controlled Equity Offering SM with Cantor Fitzgerald & Co.
- Review the attached legal opinion (Exhibit 5.1) for any conditions precedent to the stock sale.